高危前列腺癌常规影像阴性者中筛选PSMA PET/CT首选分期最佳候选者的预测模型
基于两项前瞻性试验(n=213)的cN0M0高危前列腺癌患者,21.1%经PSMA PET/CT发生淋巴结上调分期、8.9%发生转移、23.9%总体上调分期(均未经组织学确认)。多因素分析显示Gleason分级分组和系统穿刺阳性针数百分比(PPC)显著预测总体上调分期,构建的列线图内部验证AUC为0.74(95%CI 0.67-0.82),以22%为界值可使90%低风险患者免除PSMA PET/CT。
要点
- Gleason分级分组和穿刺阳性针数百分比是总体上调分期的独立预测因素。
- GG5患者总体上调分期率33.0%,显著高于GG1-4的17.6%(p=0.0097)。
- 列线图界值22%时,90%低风险患者可安全免除PSMA PET/CT。
核心结论
- 在高危前列腺癌且常规影像cN0M0患者中,Gleason分级分组和穿刺阳性针数百分比可预测PSMA PET/CT总体上调分期。
- 基于初始PSA、穿刺阳性针数百分比、Gleason分级分组和cT分期的列线图可筛选最可能从PSMA PET/CT获益的患者。
研究设计与样本
- 利用两项前瞻性试验(NCT03368547和NCT04050215)的数据,纳入常规影像cN0M0的NCCN高危前列腺癌患者213例。
- 采用多因素分析探索PSMA PET/CT总体上调分期(淋巴结和/或转移)的预测因素,并构建列线图进行内部验证。
主要发现
- 21.1%患者发生淋巴结上调分期,8.9%发生转移,23.9%发生总体上调分期,均未经组织学确认。
- 多因素分析中Gleason分级分组预测总体上调分期的OR为2.15(95%CI 1.33-3.45,p=0.002),穿刺阳性针数百分比的OR为1.03(95%CI 1.01-1.04,p<0.001)。
- GG5患者总体上调分期率33.0%,GG1-4患者为17.6%(p=0.0097);穿刺阳性针数百分比≥50%者为33.0%,<50%者为15.0%(p=0.0020)。
- 列线图内部验证的十折交叉验证AUC为0.74(95%CI 0.67-0.82)。
- 以22%为总体上调分期风险界值,90%低于界值的患者可免除PSMA PET/CT,模型仅漏掉10%本可获益的患者。
关键数值与推荐
- 列线图预测总体上调分期的界值为22%。
- 列线图基于初始PSA、穿刺阳性针数百分比、Gleason分级分组和cT分期构建。
临床怎么用
- 对于常规影像cN0M0的高危前列腺癌患者,可依据Gleason分级分组和穿刺阳性针数百分比评估PSMA PET/CT总体上调分期风险。
- 列线图预测风险低于22%的患者可考虑免除PSMA PET/CT,减少不必要的检查。
局限性
- 上调分期未经组织学确认。
- 列线图仅进行内部验证,需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is an emerging imaging modality with greater sensitivity and specificity over conventional imaging for prostate cancer (PCa) staging. Using data from two prospective trials (NCT03368547 and NCT04050215), we explored predictors of overall upstaging (nodal and metastatic) by PSMA PET/CT among patients with cN0M0 National Comprehensive Cancer Network high-risk PCa on conventional imaging (n = 213). Overall, 21.1%, 8.9%, and 23.9% of patients experienced nodal, metastatic, and overall upstaging, respectively, without histologic confirmation. On multivariable analysis, Gleason grade group (GG) and percent positive core (PPC) on systematic biopsy significantly predict overall upstaging (odds ratio [OR] 2.15, 95% confidence interval [CI] 1.33-3.45; p = 0.002; and OR 1.03, 95% CI 1.01-1.04; p < 0.001). Overall upstaging was significantly more frequent among men with GG 5 disease (33.0% vs. 17.6%; p = 0.0097) and PPC ≥50% (33.0% vs 15.0%; p = 0.0020). We constructed a nomogram that predicts overall upstaging using initial prostate-specific antigen, PPC, GG, and cT stage, with coefficients estimated from a standard logistic regression model (using maximum likelihood estimation). It is internally validated with a tenfold cross-validated area under the receiver operating characteristic curve estimated at 0.74 (95% CI 0.67-0.82). In our cohort, 90% of patients who had a nomogram-estimated risk below the cutoff of 22% for overall upstaging could have been spared PSMA PET/CT as our model correctly predicted no upstaging. In other words, the predictive model only missed 10% of patients who would otherwise have benefitted from PSMA PET/CT. PATIENT SUMMARY: We analyzed predictors of overall upstaging (lymph node or/and metastasis) by prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) from conventional imaging in men with high-risk prostate cancer undergoing initial staging deemed free of disease in the lymph nodes and distant metastasis by conventional imaging techniques. We found that the pathologic grade and disease burden in a prostate biopsy are associated with upstaging. We also developed a tool that predicts the probability of upstaging according to an individual patient's characteristics. Our study may help in defining patient groups who are most likely to benefit from the addition of a PSMA PET/CT scan.
引用
- Ma TM, Gafita A, Shabsovich D, et al. Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. Eur Urol Oncol. 2021. PMID: 33602654. doi:10.1016/j.euo.2021.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。